The importance of robust genomic testing for patients
Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.
Clinical Scorecard: The importance of robust genomic testing for patients
At a Glance
Category Detail
Condition Lung Cancer Key Mechanisms Identification of actionable genomic targets for targeted inhibitors. Target Population Patients with ALK-positive non-small cell lung cancer. Care Setting Precision oncology.
Key Highlights
Robust genomic testing is crucial for appropriate targeted therapy. Median progression-free survival for ALK-positive patients treated with lorlatinib has not yet been reached. Third-generation ALK inhibitors can lead to long-term, durable remission. Guideline-Based Recommendations
Diagnosis
Utilize genomic testing to identify ALK-positive status in lung cancer patients. Management
Administer lorlatinib as a frontline treatment for ALK-positive non-small cell lung cancer. Monitoring & Follow-up
Monitor progression-free survival and response to treatment in patients receiving targeted inhibitors. Risks
Consider the emotional and clinical implications of a lung cancer diagnosis. Patient & Prescribing Data
Patients diagnosed with ALK-positive non-small cell lung cancer.
Third-generation ALK inhibitors have shown potential for transforming lung cancer into a manageable chronic condition.
Clinical Best Practices
Implement robust genomic testing as a standard practice in lung cancer treatment. Ensure timely access to targeted therapies for eligible patients. Related Resources & Content
